rev: November 18, 1999
HOME (index page)
Return (alphabetical antibody page)
Return (cytokeratin data page)
CYTOKERATIN
ANTIBODIES
(anti-Human and others as indicated)
RDI Division of Fitzgerald Industries Intl offers a wide line of antibodies. Since no one antibody works best for all applications (neutralization, blotting, ELISA, etc), we offer many different types of antibodies to help solve this problem. Please inquire for other applications or types of antibodies not listed below.
ANTI-CYTOKERATIN TYPE 19
Mab to Cytokeratin 19
cat#RDI-PRO61010 (same as cat#RDI-CBL178) $375.00/vial
Clone Determination Ks 19.1
Category Mouse monoclonal
Immunoglobulin Class IgG2a
Purification SpAss-Protein A (recombinant)
Antigen Cytokeratin 19 of Mr 40000; from cultured human MCF-7 cells
Specificity Ks 19.1 represents an excellent marker to discriminate glandular
epithelial Ca from those of different origin. No reaction with hepatocellular
Ca!
Application Suitable for
· frozen tissue
-paraffin embedded tissue
· immunoblotting (Western)
· cytological Material
Stability/Storage One year after reconstitution when stored at 4°C
Quantity 50 µg (lyoph.) contain 0.5% BSA and 0.09% NaN3
Polypeptide Reacting MR 40 000 polypeptide (cytokeratin 19) of human glandular
epithelia
Antigen Recognized in species tested so far: Human
Reactivities on Cultured
MCF-7, RT 122, HT-29, Detroit 562, RPMI 2650, SSC-12, HT-29
Cell Lines (tested so far)
Structures and Tissues specifically detcetd: All tested adeno CA; cholangio
CA of liver; renal cell CA; transitional cell of CA of bladder; ovary CA;
squamous cell CA of cervix, bronchus and lung (inter-mediate type); mesothelioma;
carcinoid tumor of ronchus; breast CA; thymoma
Working Dilution When reconstituted with 1ml distilled water dilute 1:10
with PBS (pH7.2) for immunohistochemistry
Incubation: 1HR RT
References
-Balaton, A.J. et al, Distinction between hepatocellular carcinoma, cholangiocarcinoma, and metastatic carcinoma based on immunohistochemical staining for carcinoembryonic antigen and for cytokeratin 19 on paraffin sections. J. Pathol 156, 305-310 (1988)
-Dockhorn-Dworniczak et al:Patterns of expression of cytoskeletal proteins in human thyroid gland and thyroid carcinomas. Differentiation 35, 53-71 (1987)
-Franke, W.W., Moll, R et al:Cell typing of epithelia and carcinomas of the female genital tract using cytoskeletal proteins as markers, Banbury Report 21:Viral Etiology of Cervical Cancer, Cold Spring Harbor Laboratory (NY) 121-148 (1986)
-Karsten U et al, Monoclonal anti-cytokeratin antibody from a hybridoma clone generated by electrofusion. Eur J Cancer Clin Oncol 21, 733-740 (1985)
-Kasper, M. et al, Histological evaluation of three new monoclonal anti-cytokeratin antibodies 1:Normal tissues Eur J Cancer Clin oncol. 23, 137-147 (1987)
-Lindberg K et al:Suprabasal 40kD keratin (K19) expression as an immunohistochemical marker of premalignancy in oral epithelium. Am J. Pathol 134, 89-98 (1989)
-Moll, R et al:The catalog of human cytokeratins:Patterns of expression in normal epithelia, tumors and cultured cells. Cell 31, 11-24 (1982
-Demirkesen C et al, Epithelial markers and differentiation in adnexal neoplasms of the skin:an immunohistochemical study including individual cytokeratins. J. Cutan Pathol 22:518-535 (1995)
For research use only. Not supplied for use in human diagnostic or therapeutic procedures
34 Junction Square Drive
Concord MA 01742-3049
USA
phone (978) 371-6446 or (800) 370-2222
fax (978) 371-2266
EMAIL:antibodies@fitzgerald-fii.com
RETURN(cytokeratin page)